Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports

• 主要な著者: Renato Cutrera (著者), Andrea Wolfler (著者), Simonetta Picone (著者), Giovanni A. Rossi (著者), Giuliana Gualberti (著者), Rocco Merolla (著者), Antonio Del Vecchio (著者), Alberto Villani (著者), Fabio Midulla (著者), Andrea Dotta (著者)
• フォーマット: 図書
• 出版事項: BMC, 2019-11-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract Background The only pharmacologic prophylaxis against respiratory syncytial virus (RSV) infection in preterm infants is the humanized monoclonal antibody palivizumab. After the 2014 modification of the American Academy of Pediatrics (AAP) recommendations, the Italian Medicines Agency (AIFA)...